CoChat
Sign Up
Cited by 62Cancer-related molecular mechanisms researchRNA modifications and cancerMicroRNA in disease regulation

snoRNAs offer novel insight and promising perspectives for lung Cancer understanding and management

Open access
Mourksi, Nour-El-Houda, Morin, Chloé, Fenouil, Tanguy, Diaz, Jean-Jacques, Marcel, Virginie·2020·Cells
DOI 10.3390/cells9030541PMC PMC7140444
Open this paper in CoChat — free accountOpen PDF

Abstract

Small nucleolar RNAs (snoRNAs) are non-coding RNAs localized in the nucleolus, where they participate in the cleavage and chemical modification of ribosomal RNAs. Their biogenesis and molecular functions have been extensively studied since their identification in the 1960s. However, their role in cancer has only recently started to emerge. In lung cancer, efforts to profile snoRNA expression have enabled the definition of snoRNA-related signatures, not only in tissues but also in biological fluids, exposing these small RNAs as potential non-invasive biomarkers. Moreover, snoRNAs appear to be essential actors of lung cancer onset and dissemination. They affect diverse cellular functions, from regulation of the cell proliferation/death balance to promotion of cancer cell plasticity. snoRNAs display both oncogenic and tumor suppressive activities that are pivotal in lung cancer tumorigenesis and progression. Altogether, we review how further insight into snoRNAs may improve our understanding of basic lung cancer biology and the development of innovative diagnostic tools and therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9030541

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is evidence that malignant cells of lung cancer tissue in primary cultures and lung cancer cell lines express members of the SNORD115 cluster, in addition to many other SNORDs and SNORAs.

    “Although it has been reiterated in recent publications, (Cavaillé, 2017; Chung et al., 2020; Deogharia and Majumder, 2018), there is evidence that malignant cells of lung cancer tissue in primary cultures and lung cancer cell lines express members of SNORD115 cluster, in addition to many other SNORDs and SNORAs (Gao et al., 2014; Liao et al., 2010; Mourksi et al., 2020).”

    From Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer's disease (2021) · cites this paper as Mourksi et al., 2020

    Sections 4.1 and 5 report SNORA and SNORD expression in lung cancer tissue and cell lines. But section 2.3 mentions SNORD115 only as part of a locus associated with Prader–Willi syndrome; the cited passages do not establish SNORD115-cluster expression in lung cancer cells. Section 4.1 describes primary surgical specimens, not primary cultures. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. [1]Palazzo A.F. Lee E.S. Non-coding RNA: What is functional and what is junk? Front. Genet. 2015 6 2 10.3389/fgene.2015.00002 25674102 PMC4306305 · DOI
  2. [2]Peng Y. Croce C.M. The role of microRNAs in human cancer Signal Transduct. Tar. 2016 1 9 10.1038/sigtrans.2015.4 29263891 PMC5661652 · DOI
  3. [3]Gong J. Li Y. Liu C.-J. Guo A.-Y. Lin C. Correspondence H. A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer Cell Rep. 2017 21 1968 1981 10.1016/j.celrep.2017.10.070 29141226 · DOI
  4. [4]Knight S.B. Crosbie P.A. Balata H. Chudziak J. Hussell T. Dive C. Progress and prospects of early detection in lung cancer Open Biol. 2017 7 PMC5627048 28878044
  5. [6]Maxwell E. Fournier M. The Small Nucleolar RNAs Annu. Rev. Biochem. 1995 64 897 934 10.1146/annurev.bi.64.070195.004341 7574504 · DOI · Paper page
  6. [7]Stern H. Johnston F. Setterfield G. Some chemical properties of isolated pea nucleoli J. Biophys. Biochem. Cytol. 1959 6 57 60 10.1083/jcb.6.1.57 13673047 PMC2229772 · DOI
  7. [8]Kufel J. Grzechnik P. Small Nucleolar RNAs Tell a Different Tale Trends Genet. 2019 35 104 117 10.1016/j.tig.2018.11.005 30563726 · DOI
  8. [9]Lafontaine D.L.J. Noncoding RNAs in eukaryotic ribosome biogenesis and function Nat. Struct. Mol. Biol. 2015 22 11 19 10.1038/nsmb.2939 25565028 · DOI
  9. [10]Jorjani H. Kehr S. Jedlinski D.J. Gumienny R. Hertel J. Stadler P.F. Zavolan M. Gruber A.R. An updated human snoRNAome Nucleic Acids Res. 2016 44 5068 5082 10.1093/nar/gkw386 27174936 PMC4914119 · DOI · Paper page
  10. [11]Dieci G. Preti M. Montanini B. Eukaryotic snoRNAs: A paradigm for gene expression flexibility Genomics 2009 94 83 88 10.1016/j.ygeno.2009.05.002 19446021 · DOI
  11. [12]Balakin A.G. Smith L. The RNA World of the Nucleolus: Two Major Families of Small RNAs Defined by Different Box Elements with Related Functions Cell 1996 86 823 834 10.1016/S0092-8674(00)80156-7 8797828 · DOI
  12. [14]Massenet S. Bertrand E. Verheggen C. Assembly and trafficking of box C/D and H/ACA snoRNPs RNA Biol. 2017 14 680 692 10.1080/15476286.2016.1243646 27715451 PMC5519232 · DOI
  13. [15]Lo Monaco P. Marcel V. Diaz J.J. Catez F. 2′-O-methylation of ribosomal RNA: Towards an epitranscriptomic control of translation? Biomolecules 2018 8 106 10.3390/biom8040106 PMC6316387 30282949 · DOI
  14. [16]Tollervey D. Kiss T. Function and synthesis of small nucleolar RNAs Curr. Opin. Cell Biol. 1997 9 337 342 10.1016/S0955-0674(97)80005-1 9159079 · DOI
  15. [17]Therizols G. Laforêts F. Marcel V. Catez F. Bouvet P. Diaz J.J. Ribosomal RNA Methylation and Cancer Epigenetic Cancer Therapy Academic Press Cambridge, MA, USA 2015 115 139 9780128002247
  16. [18]Kass S. Tyc K. Steitz J.A. Sollner-Webb B. The U3 small nucleolar ribonucleoprotein functions in the first step of preribosomal RNA processing Cell 1990 60 897 908 10.1016/0092-8674(90)90338-F 2156625 · DOI
  17. [19]Langhendries J.-L. Nicolas E. Doumont G. Goldman S. Lafontaine D.L.J. The human box C/D snoRNAs U3 and U8 are required for pre-rRNA processing and tumorigenesis Oncotarget 2016 7 59519 59534 10.18632/oncotarget.11148 27517747 PMC5312328 · DOI
  18. [20]Zhong F. Zhou N. Wu K. Guo Y. Tan W. Zhang H. Zhang X. Geng G. Pan T. Luo H. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes Nucleic Acids Res. 2015 43 10474 10491 10.1093/nar/gkv954 26405199 PMC4666397 · DOI
  19. [21]Ender C. Krek A. Friedländer M.R. Beitzinger M. Weinmann L. Chen W. Pfeffer S. Rajewsky N. Meister G. A Human snoRNA with MicroRNA-Like Functions Mol. Cell 2008 32 519 528 10.1016/j.molcel.2008.10.017 19026782 · DOI
  20. [22]Huang C. Shi J. Guo Y. Huang W. Huang S. Ming S. Wu X. Zhang R. Ding J. Zhao W. A snoRNA modulates mRNA 3′ end processing and regulates the expression of a subset of mRNAs Nucleic Acids Res. 2017 45 8647 8660 10.1093/nar/gkx651 28911119 PMC5587809 · DOI
  21. [23]Falaleeva M. Pages A. Matuszek Z. Hidmi S. Agranat-Tamir L. Korotkov K. Nevo Y. Eyras E. Sperling R. Stamm S. Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing Proc. Natl. Acad. Sci. USA 2016 113 E1625 E1634 10.1073/pnas.1519292113 26957605 PMC4812717 · DOI
  22. [24]Sahoo T. Del Gaudio D. German J.R. Shinawi M. Peters S.U. Person R.E. Garnica A. Cheung S.W. Beaudet A.L. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster Nat. Genet. 2008 40 719 721 10.1038/ng.158 18500341 PMC2705197 · DOI
  23. [25]Falaleeva M. Welden J.R. Duncan M.J. Stamm S. C/D-box snoRNAs form methylating and non-methylating ribonucleoprotein complexes: Old dogs show new tricks BioEssays 2017 39 10.1002/bies.201600264 28505386 PMC5586538 · DOI
  24. [26]Zhou F. Liu Y. Rohde C. Pauli C. Gerloff D. Köhn M. Misiak D. Bäumer N. Cui C. Göllner S. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia Nat. Cell Biol. 2017 19 844 855 10.1038/ncb3563 28650479 · DOI
  25. [27]Su H. Xu T. Ganapathy S. Shadfan M. Long M. Huang T.H.M. Thompson I. Yuan Z.M. Elevated snoRNA biogenesis is essential in breast cancer Oncogene 2014 33 1348 1358 10.1038/onc.2013.89 23542174 · DOI
  26. [28]Davanian H. Balasiddaiah A. Heymann R. Sundström M. Redenström P. Silfverberg M. Brodin D. Sällberg M. Lindskog S. Kruger Weiner C. Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature Oncotarget 2017 8 4530 4542 10.18632/oncotarget.13889 27965463 PMC5354851 · DOI
  27. [29]Wang X. Xu M. Yan Y. Kuang Y. Li P. Zheng W. Liu H. Jia B. Identification of Eight Small Nucleolar RNAs as Survival Biomarkers and Their Clinical Significance in Gastric Cancer Front. Oncol. 2019 9 788 794 10.3389/fonc.2019.00788 31552164 PMC6747046 · DOI
  28. [30]Scott M.S. Ono M. From snoRNA to miRNA: Dual function regulatory non-coding RNAs Biochimie 2011 93 1987 1992 10.1016/j.biochi.2011.05.026 21664409 PMC3476530 · DOI
  29. [31]Mannoor K. Liao J. Jiang F. Small nucleolar RNAs in cancer Biochim. Biophys. 2012 1826 121 128 10.1016/j.bbcan.2012.03.005 PMC3842010 22498252 · DOI
  30. [32]Thorenoor N. Slaby O. Small nucleolar RNAs functioning and potential roles in cancer Tumor Biol. 2014 36 41 53 10.1007/s13277-014-2818-8 25420907 · DOI
  31. [34]Barta J.A. Henschke C.I. Flores R.M. Yip R. Yankelevitz D.F. Powell C.A. Lung Cancer Diagnosis by Fine Needle Aspiration Is Associated With Reduction in Resection of Nonmalignant Lung Nodules Ann. Thorac. Surg. 2017 103 1795 1801 10.1016/j.athoracsur.2016.11.055 28274517 PMC9338773 · DOI
  32. [35]Rivera M.P. Mehta A.C. Wahidi M.M. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines Chest 2013 143 e142S e165S 10.1378/chest.12-2353 23649436 · DOI
  33. [36]Mlika M. Hofman P. Dziri C. Mezni F. Liquid biopsy in lung cancer Tunis. Med. 2017 95 965 971 29877554
  34. [37]Travis W.D. Brambilla E. Nicholson A.G. Yatabe Y.M. Austin J.H. Beth Beasley M. Chirieac L.R. Dacic S. Duhig E. Flieder D.B. The 2015 World Health Organization Classification of Lung Tumors J. Thorac. Oncol. 2015 10 1243 1260 10.1097/JTO.0000000000000630 26291008 · DOI
  35. [38]Gurda G.T. Zhang L. Wang Y. Chen L. Geddes S. Cho W.C. Askin F. Gabrielson E. Li Q.K. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: A retrospective study of 246 fine needle aspiration cases Clin. Transl. Med. 2015 4 16 10.1186/s40169-015-0057-2 25977750 PMC4417108 · DOI
  36. [39]Kashima J. Kitadai R. Okuma Y. Molecular and morphological profiling of lung cancer: A foundation for “next-generation” pathologists and oncologists Cancers 2019 11 599 10.3390/cancers11050599 PMC6562944 31035693 · DOI
  37. [40]Balsara B.R. Testa J.R. Chromosomal imbalances in human lung cancer Oncogene 2002 21 6877 6883 10.1038/sj.onc.1205836 12362270 · DOI
  38. [41]Lin J.J. Shaw A.T. Resisting Resistance: Targeted Therapies in Lung Cancer Trends Cancer 2016 2 350 364 10.1016/j.trecan.2016.05.010 27819059 PMC5091655 · DOI
  39. [42]Shames D.S. Wistuba I.I. The evolving genomic classification of lung cancer J. Pathol. 2014 232 121 133 10.1002/path.4275 24114583 PMC4285848 · DOI
  40. [43]Schallenberg S. Merkelbach-Bruse S. Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours Virchows Arch. 2017 471 221 233 10.1007/s00428-017-2183-2 28730537 · DOI
  41. [44]Gallant J.N. Lovly C.M. Established, emerging and elusive molecular targets in the treatment of lung cancer J. Pathol. 2018 244 565 577 10.1002/path.5038 29344953 PMC10182407 · DOI
  42. [45]Hata A.N. Niederst M.J. Archibald H.L. Gomez-Caraballo M. Siddiqui F.M. Mulvey H.E. Maruvka Y.E. Ji F. Bhang H.E.C. Radhakrishna V.K. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Nat. Med. 2016 22 262 269 10.1038/nm.4040 26828195 PMC4900892 · DOI · Paper page
  43. [46]Doroshow D.B. Sanmamed M.F. Hastings K. Politi K. Rimm D.L. Chen L. Melero I. Schalper K.A. Herbst R.S. Immunotherapy in non-small cell lung cancer: Facts and hopes Clin. Cancer Res. 2019 25 4592 4602 10.1158/1078-0432.CCR-18-1538 30824587 PMC6679805 · DOI
  44. [47]Mok T.S.K. Wu Y.L. Kudaba I. Kowalski D.M. Cho B.C. Turna H.Z. Castro G. Srimuninnimit V. Laktionov K.K. Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial Lancet 2019 393 1819 1830 10.1016/S0140-6736(18)32409-7 30955977 · DOI
  45. [49]Gao L. Ma J. Mannoor K. Guarnera M.A. Shetty A. Zhan M. Xing L. Stass S.A. Jiang F. Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing Int. J. Cancer 2015 136 E623 E629 10.1002/ijc.29169 25159866 · DOI · Paper page
  46. [50]Nogueira Jorge N.A. Wajnberg G. Ferreira C.G. De Sa Carvalho B. Passetti F. snoRNA and piRNA expression levels modified by tobacco use in women with lung adenocarcinoma PLoS ONE 2017 12 10.1371/journal.pone.0183410 PMC5560661 28817650 · DOI
  47. [51]Pan X. Chen L. Feng K.-Y. Hu X.-H. Zhang Y.-H. Kong X.-Y. Huang T. Cai Y.-D. Analysis of Expression Pattern of snoRNAs in Different Cancer Types with Machine Learning Algorithms Int. J. Mol. Sci. 2019 20 2185 10.3390/ijms20092185 PMC6539089 31052553 · DOI
  48. [52]Templeton A.K. Miyamoto S. Babu A. Munshi A. Ramesh R. Cancer stem cells: Progress and challenges in lung cancer Stem Cell Investig. 2014 1 PMC4923513 27358855
  49. [53]Vallette F. Olivier C. Lezot F. Oliver L. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer Biochem. Pharmacol. 2019 162 169 176 10.1016/j.bcp.2018.11.004 30414937 · DOI
  50. [54]Dawson C.C. Intapa C. Jabra-Rizk M.A. “Persisters”: Survival at the cellular level PLoS Pathog. 2011 7 10.1371/journal.ppat.1002121 21829345 PMC3145784 · DOI
  51. [55]Eramo A. Lotti F. Sette G. Pilozzi E. Biffoni M. Di Virgilio A. Conticello C. Ruco L. Peschle C. De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ. 2008 15 504 514 10.1038/sj.cdd.4402283 18049477 · DOI
  52. [56]Sharma S.V. Lee D.Y. Li B. Quinlan M.P. Takahashi F. Maheswaran S. McDermott U. Azizian N. Zou L. Fischbach M.A. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations Cell 2010 141 69 80 10.1016/j.cell.2010.02.027 20371346 PMC2851638 · DOI · Paper page
  53. [57]Raha D. Wilson T.R. Peng J. Peterson D. Yue P. Evangelista M. Wilson C. Merchant M. Settleman J. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation Cancer Res. 2014 74 3579 3590 10.1158/0008-5472.CAN-13-3456 24812274 · DOI · Paper page
  54. [58]Feng J. Qi Q. Khanna A. Todd N.W. Deepak J. Lingxiao X. Huijun W. Zhenqiu L. Yun S. Stass S.A. Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer Mol. Cancer Res. 2009 7 330 338 19276181 PMC4255559
  55. [59]Mannoor K. Shen J. Liao J. Liu Z. Jiang F. Small nucleolar RNA signatures of lung tumor-initiating cells Mol. Cancer 2014 13 10.1186/1476-4598-13-104 PMC4029979 24886050 · DOI
  56. [60]Su J. Liao J. Gao L. Shen J. Guarnera M.A. Zhan M. Fang H.B. Stass S.A. Jiang F. Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis Oncotarget 2016 7 5131 5142 10.18632/oncotarget.4219 26246471 PMC4868676 · DOI
  57. [61]Sadik N. Cruz L. Gurtner A. Rodosthenous R.S. Dusoswa S.A. Ziegler O. Van Solinge T.S. Wei Z. Salvador-Garicano A.M. Gyorgy B. Extracellular RNAs: A new awareness of old perspectives Methods Mol. Biol. 2018 1740 1 15 29388131 PMC6509047
  58. [62]Shen J. Todd N.W. Zhang H. Yu L. Lingxiao X. Mei Y. Guarnera M. Liao J. Chou A. Lu C.L. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer Lab. Investig. 2011 91 579 587 10.1038/labinvest.2010.194 21116241 PMC3130190 · DOI
  59. [63]Xie Y. Todd N.W. Liu Z. Zhan M. Fang H.B. Peng H. Alattar M. Deepak J. Stass S.A. Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer Lung Cancer 2010 67 170 176 10.1016/j.lungcan.2009.04.004 19446359 PMC2846426 · DOI · Paper page
  60. [64]Pardini B. Sabo A.A. Birolo G. Calin G.A. Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies Cancers 2019 11 1170 10.3390/cancers11081170 31416190 PMC6721601 · DOI
  61. [65]Savelyeva A.V. Kuligina E.V. Bariakin D.N. Kozlov V.V. Ryabchikova E.I. Richter V.A. Semenov D.V. Variety of RNAs in Peripheral Blood Cells, Plasma, and Plasma Fractions Biomed. Res. Int. 2017 2017 7404912 10.1155/2017/7404912 28127559 PMC5239830 · DOI
  62. [66]Su Y. Guarnera M.A. Fang H.B. Jiang F. Small non-coding RNA biomarkers in sputum for lung cancer diagnosis Mol. Cancer 2016 15 10.1186/s12943-016-0520-8 27176474 PMC4866414 · DOI
  63. [67]Tang G. Zeng Z. Sun W. Li S. You C. Tang F. Peng S. Ma S. Luo Y. Xu J. Small nucleolar RNA 71A promotes lung cancer cell proliferation, migration and invasion via MAPK/ERK pathway J. Cancer 2019 10 2261 2275 10.7150/jca.31077 31258730 PMC6584411 · DOI
  64. [68]Siprashvili Z. Webster D.E. Johnston D. Shenoy R.M. Ungewickell A.J. Bhaduri A. Flockhart R. Zarnegar B.J. Che Y. Meschi F. The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer Nat. Genet. 2016 48 53 58 10.1038/ng.3452 26595770 PMC5324971 · DOI
  65. [69]Okugawa Y. Toiyama Y. Toden S. Mitoma H. Nagasaka T. Tanaka K. Inoue Y. Kusunoki M. Boland C.R. Goel A. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer Gut 2017 66 107 117 10.1136/gutjnl-2015-309359 26475630 PMC4860159 · DOI
  66. [70]Mei Y.P. Liao J.P. Shen J. Yu L. Liu B.L. Liu L. Li R.Y. Ji L. Dorsey S.G. Jiang Z.R. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis Oncogene 2012 31 2794 2804 10.1038/onc.2011.449 21986946 PMC4966663 · DOI
  67. [71]Yi C. Wan X. Zhang Y. Fu F. Zhao C. Qin R. Wu H. Li Y. Huang Y. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis Int. J. Biochem. Cell Biol. 2018 102 138 150 10.1016/j.biocel.2018.07.009 30053504 · DOI
  68. [72]Zheng D. Zhang J. Ni J. Luo J. Wang J. Tang L. Zhang L. Wang L. Xu J. Su B. Small nucleolar RNA 78 promotes the tumorigenesis in non-small cell lung cancer J. Exp. Clin. Cancer Res. 2015 34 10.1186/s13046-015-0170-5 PMC4472183 25975345 · DOI
  69. [73]Sahai E. Mechanisms of cancer cell invasion Curr. Opin. Genet. Dev. 2005 15 87 96 10.1016/j.gde.2004.12.002 15661538 · DOI
  70. [74]Ma C. Shi X. Zhu Q. Li Q. Liu Y. Yao Y. Song Y. The growth arrest-specific transcript 5 (GAS5): A pivotal tumor suppressor long noncoding RNA in human cancers Tumor Biol. 2016 37 1437 1444 10.1007/s13277-015-4521-9 26634743 · DOI
  71. [75]Hou J. Aerts J. Den Hamer B. Van IJcken W. Den Bakker M. Riegman P. Van der Leest C. Van der Spek P. Foekens J.A. Hoogsteden H.C. Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction PLoS ONE 2010 5 e10312 10.1371/journal.pone.0010312 20421987 PMC2858668 · DOI
  72. [77]Hein N. Hannan K.M. George A.J. Sanij E. Hannan R.D. The nucleolus: An emerging target for cancer therapy Trends Mol. Med. 2013 19 643 654 10.1016/j.molmed.2013.07.005 23953479 · DOI
  73. [78]Marcel V. Catez F. Diaz J.J. Ribosome heterogeneity in tumorigenesis: The rRNA point of view Mol. Cell. Oncol. 2015 2 10.4161/23723556.2014.983755 PMC4905297 27305893 · DOI
  74. [79]Jantsch M.F. Quattrone A. O’Connell M. Helm M. Frye M. Macias-Gonzales M. Ohman M. Ameres S. Willems L. Fuks F. Positioning Europe for the EPITRANSCRIPTOMICS challenge RNA Biol. 2018 15 829 831 10.1080/15476286.2018.1460996 29671387 PMC6152430 · DOI
  75. [80]Erales J. Marchand V. Panthu B. Gillot S. Belin S. Ghayad S.E. Garcia M. Laforêts F. Marcel V. Baudin-Baillieu A. Evidence for rRNA 2′-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes Proc. Natl. Acad. Sci. USA 2017 114 12934 12939 10.1073/pnas.1707674114 29158377 PMC5724255 · DOI
  76. [81]Marcel V. Ghayad S.E. Belin S. Therizols G. Morel A.P. Solano-Gonzàlez E. Vendrell J.A. Hacot S. Mertani H.C. Albaret M.A. P53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer Cancer Cell 2013 24 318 330 10.1016/j.ccr.2013.08.013 24029231 PMC7106277 · DOI
  77. [82]Gachet S. El-Chaar T. Avran D. Genesca E. Catez F. Quentin S. Delord M. Thérizols G. Briot D. Meunier G. Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation Cancer Discov. 2018 8 1614 1631 10.1158/2159-8290.CD-17-0831 30266814 · DOI
  78. [83]Justilien V. Ali S.A. Jamieson L. Yin N. Cox A.D. Der C.J. Murray N.R. Fields A.P. Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma Cancer Cell 2017 31 256 269 10.1016/j.ccell.2016.12.010 28110998 PMC5310966 · DOI
  79. [84]Hanna J. Hossain G.S. Kocerha J. The potential for microRNA therapeutics and clinical research Front. Genet. 2019 10 10.3389/fgene.2019.00478 31156715 PMC6532434 · DOI
  80. [85]Christopher A. Kaur R. Kaur G. Kaur A. Gupta V. Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy Perspect. Clin. Res. 2016 7 68 27141472 PMC4840794

Cited by

Sorted by citations

Authors
Mourksi, N.-E.-H., Morin, C., Fenouil, T., Diaz, J.-J., & Marcel, V.
Affiliations
Lyon 1 Université (FR)
Corresponding author
Marcel, Virginie
ORCID
Venue
Cells
Publisher
MDPI AG
Published
2020-02-26
Volume
9
Issue
3
Pages
541
ISSN
2073-4409 (ISSN-L)
DOI
10.3390/cells9030541
PMC
PMC7140444
OpenAlex
W3006878801
Cited by
62
References
3
Citations by year
2026: 2 · 2025: 11 · 2024: 7 · 2023: 8 · 2022: 20 · 2021: 10 · 2020: 4
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Cells (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Institut National Du Cancer (PLBIO 2019-138, INCa-DGOS-Inserm_12563)
  • Institut National de la Santé et de la Recherche Médicale (18CN044-00)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
small nucleolar RNA, lung cancer, non-coding RNA, nucleolus, liquid biopsy biomarkers, tumor progression, tumor plasticity, cell proliferation and apoptosis, lung cancer diagnosis, lung cancer treatment
MeSH terms
Animals, Humans, Lung Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, RNA, Small Nucleolar, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review